参考文献/References:
[1] Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol, 2009, 33(5):315-318.
[2] American College of Radiology. Breast imaging reporting and data system (BI-RADS). 4th ed. Reston:American College of Radiology, 2003:1-259.
[3] Feig SA. Ductal carcinoma in situ. Implications for screening mammorgraphy. Radiol Clin North Am, 2000, 38(4):653-668, vii.
[4] 李树玲.乳腺肿瘤学.北京:科学技术文献出版社,2000:306.
[5] 杨季红,李靖华,陈治,等.女性乳腺癌组织雄激素受体的表达与临床病理学指标的研究[J].河北医药,2011,33(4):527-529.
[6] 葛怀娥,臧春霞,李红文,等.ER与PR在钼靶X线假阴性乳腺癌中的表达及临床意义[J].河北医药,2009,31(7):805-806.
[7] Choi BB, Shu KS. Metaplastic carcinoma of the breast:muhimodality imaging and histopathologie assessment. Acta Radiol, 2012, 53(1):5-11.
[8] 陈红秋,粟连秀,杨达平,梁立盛.ER、PR、C-erbB-2及p53在乳腺癌中的表达及意义[J].广西医学,2008,30(3):343-344.
[9] Narod SA, Valentini A, Nofech-Mozes S, et al. Tumour characteristics among women with very low-risk breast cancer[J/OL]. Breast Cancer Res Treat, 2012, 134(3):1241-1246[2012-05-07]. http://www.springerlink.com/content/n645934798hlq586/.[published online ahead of print august, 2012].
[10] Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medi-cal therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat, 2001, 66(3):191-199.
[11] Gajdos C, Tartter PI, Bleiweiss IJ, et al. Stage 0 to stage Ⅲ breast cancer in young women. J Am Coll Surg, 2000, 190(5):523-529.
[12] Boyd NF, Martin LJ, Yaffe MJ, et al. Mammographic density and breast cancer risk:current understanding and future prospects. Breast Cancer Res, 2011, 13(6):223-234.
[13] Ma H, Luo J, Press MF, et al. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev, 2009, 18(2):479-485.
[14] Conroy SM, Pagano I, Kolonel LN, et al. Mammographie density and hormone receptor expression in breast cancer:the Multiethnic Cohort Study. Cancer Epidemiol, 2011, 35(5):448-452.
[15] Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst, 2011, 103(15):1179-1189.
[16] Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat, 2008, 111(3):405-410.
[17] Ghosh K, Brandt KR, Sellers TA, et al. Association of mammagraphic density with the pathology of subsequent breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev, 2008, 17(4):872-879.
[18] 李靖华,王晓春,杨季红.雄激素受体与乳腺癌关系的研究进展[J].河北医药,2011,33(2):259-260.
[19] Jiang L, Ma T, Moran MS, et al. Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. Anticancer Res, 2011, 31(6):2327-2334.
[20] Yang TJ, Yang Q, Haffty BG, et aLP Prognosis for mammographicaily occult, early-stage breast cancer patients treated with breastconservation therapy. Int J Radiat Oncol Biol Phys, 2010, 76(1):79-84.
[21] 鲍润贤.中华影像医学[M].北京:人民卫生出版社,2002.68-88.
[22] 孙清慧,任立军,郭峰.乳腺癌的钼钯X线表现与ER、PR及c-erbB-2表达的相关性[J].山东医药,2008,48(23):65-66.
[23] 孙辉,石毅然.乳腺癌的ER、PR、C-erbB-2表达与钼靶X线表现相关性研究[J].中国中医药现代远程教育,2008(10):1237-1238.
[24] Tabár L, Chen HH, Duffy SW, et al. A novel method for prediction of long-term outcome of women with Tla, Tlb, and 10-14 mm invasive breast cancers:a prospective study. Lancet, 2000, 355(9202):429-433.
[25] 张嫣,郭庆禄,张江宇,等.乳腺癌钼靶X线表现与ER、PR及Her-2因子表达的相关性研究[J].影像诊断与介入放射学,2007,16(5):207-211.
[26] 玄东春,何娟.老年女性乳腺癌全数字化钼靶X线表现与雌激素受体的相关性[J].中国老年学杂志,2010(23):3485-3487.
[27] 陈蓉,龚水根,张伟国,何双梧,张连阳,李增鹏[3].乳腺浸润性导管癌:钼靶X线表现与雌激素受体水平的关系[J].临床放射学杂志,2003,22(5):390-393.
[28] 钱超文,徐栋,边晔萍,朱慧能,陈丽羽.乳腺癌彩色多普勒超声显像与ER、PR、CerbB-2的表达及意义[J].中国肿瘤,2005,14(5):339-341.
[29] Narod SA. Age of diagnosis, tumor size, and survival after breast cancer:implications for mammographic screening. Breast Cancer Res Treat, 2011,128(1):259-266.
[30] Ildefonso C, Vazquez J, Guinea O, et al. The mammographic appearance of breast carcinomas of invasive ductal type:relationship with clinicopatholo-cal parameters, biological features and prognosis. Eur J Obstet Gvneeol Reorod Biol, 2008, 136(2):224-231.
[31] 罗凤荣,卢功源,李雁平.乳腺癌钼靶X线表现与ER、PR、C-erbB-2表达相关性研究[J].广西医学,2009,31(3):339-341.
[32] 葛怀娥,臧春霞,白希永,等.C-erbB-2和雌激素受体及孕激素受体在钼靶X线假阴性乳腺癌中的表达及临床意义[J].河北医药,2011,33(12):1779-1781.
[33] Sakka E, Prentza A, Koutsouris D. Classification algorithms for microcalcifications in mammograms (Review). Oncol Rep, 2006, 15(4):1049-1055.
[34] 张嫣,郭庆禄,张江宇,等.乳腺癌钼靶x线表现与p53表达的相关性探讨.广州医学,2007,39(1):54-56.
[35] Karamouzis MV, Likaki-Karatza E, Ravazoula P, et al. Non-palpable breast carcinomas:correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer, 2002, 102(l):86-90.
[36] 齐晨晖,陈方满,向军益,卢林民.乳腺癌钼靶X线表现与ER、PR和P53表达的相关性探讨[J].实用放射学杂志,2010(6):871-875.
[37] Wang X Chao L, Chen L, et al. Correlation of mammographic cal-eifications with Her-2/neu overexpression in primary breast eareinomas. J Digit Imaging, 2008, 21(2):170-176.
[38] 于霞,孟菲,徐海龙,等.乳腺癌X线摄影恶性钙化征象与其预后因素的相关性分析[J].实用放射学杂志,2008,24(6):821-823.
[39] Ko ES, Lee BH, Kim HA, et al. Triple-negative breast cancer:correlation between imaging and pathological findings. Eur Radiol, 2010,20(5):1111-1117.
[40] Evans A.1, Pinder SE, Ellis IO, et al. Correlations between the mammographic features of duetal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. Clin Radiol, 1994, 49(8):559-562.
[41] Pálka I, Ormándi K, Gaál S, et al. Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients. Acta Oncol, 2007, 46(8):1178-1183.
[42] 马捷,徐坚民,孙国平,等.乳腺结构扭曲征象的X线分析[J].中国医学影像技术,2007,23(4):527-531.
[43] 杨忠,马捷,徐坚民,等.乳腺癌钼靶X线表现与c-erbB-2,ER,PR蛋白表达的相关性[J].第四军医大学学报,2007,28(21):1996-1999.
[44] 胡俊艳,殷国玮,沈卫达.乳腺癌钼靶X线表现与雌激素受体、孕激素受体及人表皮生长因子受体-2的关系[J].现代肿瘤医学,2010,18(7):1311-1313.
[45] Colditz GA, Rosner BA, Chen WY, etal. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst, 2004, 96(3):218-228.
[46] 马捷,左敏,孙国平,王国红,王晓玫,徐坚民.乳腺癌钼靶X线表现与雌激素受体表达相关性的研究[J].医学影像学杂志,2006,16(1):11-14.
相似文献/References:
[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[9]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[10]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[11]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[12]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[13]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
[14]王宇峰,刘海娜,张居洋,等.SPECT/CT融合显像对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2014,38(6):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
Wang Yu-feng,Liu Hai-na,Zhang Ju-yang,et al.Clinical value of SPECT/CT fusion imaging in diagnosing metastatic bone lesions in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
[15]董佳佳,章斌.多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较[J].国际放射医学核医学杂志,2014,38(6):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
Dong Jia-jia,Zhang Bin.Comparision on the values of different image modalities in monitoring the response to neoadjuvant chemotherapy in breast cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
[16]袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
[17]袁建伟,杨劼,贺小红,等.18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值[J].国际放射医学核医学杂志,2013,37(4):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Diagnosis value of 18F-FDG PET/CT and 3.0T MRI combined imaging in detecting the primary focus of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
[18]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[19]樊孝廉,鲁胜男,古炎发,等.乳腺癌患者骨病灶SPECT/CT融合显像的临床价值[J].国际放射医学核医学杂志,2013,37(4):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
FAN Xiao-lian,LU Sheng-nan,GU Yan-fa,et al.The clinical value of SPECT/CT fusion imaging in the diagnosis of bone metastasis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
[20]夏晓天,张永学.影像学检查在乳腺癌的诊断及疗效评估中的应用价值[J].国际放射医学核医学杂志,2010,34(4):242.[doi:10.3760/cma.j.issn.1673-4114.2010.04.014]
XIA Xiao-tian,ZHANG Yong-xue.The value of imaging examinations in diagnosis and curative effect evaluation of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):242.[doi:10.3760/cma.j.issn.1673-4114.2010.04.014]